Thank you for your inquiry.
We will contact you within a few business days.
(Business Unit Performance Materials, Sales Support Team)
Gedung AIA Central, Level 39, Jl. Jend. Sudirman Kav. 48A, Jakarta Selatan, Indonesia
+62 21 2988 8557
Success! Your inquiry has been submitted to our Sales team.
Something went wrong! Please try after some time.
We have found 51 items.
Requestor's contact details | |
Full name | |
Company | |
Position | |
Telephone number | |
Work email address | |
Shipping address |
Thank you. Your request has been sent.
ACEMETACINE is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of osteoarthritis, rheumatoid arthritis, lower back pain, and relieving post-operative pain.
Products still subject to third-party patent protection might be available solely for R&D purposes.
FAVIPIRAVIR is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections, including SARS-CoV-2.
Products still subject to third-party patent protection might be available solely for R&D purposes.
MIRABEGRON, sold under the brand name Myrbetriq among others, is a medication used to treat overactive bladder. Its benefits are similar to antimuscarinic medication.
Products still subject to third-party patent protection might be available solely for R&D purposes.
EDOXABAN TOSYLATE is an anticoagulant medication and a direct factor Xa inhibitor.
Products still subject to third-party patent protection might be available solely for R&D purposes.
ALITRETINOINE, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. It is a first generation retinoid.
Products still subject to third-party patent protection might be available solely for R&D purposes.
TRIMEBUTINE MALEATE is a drug with antimuscarinic and weak mu opioid agonist effects. It is used for the treatment of irritable bowel syndrome andother gastrointestinal disorders.
Products still subject to third-party patent protection might be available solely for R&D purposes.